A New Way to Treat BCC: Verrica’s VP-315 Shrinks Tumors, Boosts Immune Response in Phase 2 Study
VP-315 (ruxotemitide), a novel oncolytic peptide immunotherapy, continues to show promise for the treatment of basal cell carcinoma (BCC), according to new Phase 2 study results presented at the Society for Immunotherapy of Cancer 40th Annual Meeting in National Harbor, MD.